10 years 0.01
Extreme 0.01
0.06
Manager TitleAgeSince
Chief Executive Officer 67 24/05/2021
Chief Tech/Sci/R&D Officer - -
General Counsel - -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-.--% 16.43L
-1.87%+4.22%+45.93%-0.47% 8.42TCr
-0.57%+1.27%-17.24%-34.99% 6.05TCr
-2.23%+5.48%+499.46%+29.31% 5.94TCr
-2.03%-2.62%-7.46%+27.87% 5.03TCr
-4.58%-2.73%+2.93%+157.71% 4.89TCr
-1.64%+1.07%+57.80%-17.34% 3.32TCr
-0.98%+1.91%+48.35%+95.93% 2.59TCr
-0.19%-4.74%+2.30%+196.81% 2.28TCr
-1.13%-2.45%+65.99%+110.75% 1.67TCr
Average -1.40%-0.28%+69.81%+56.56% 4.02TCr
Weighted average by Cap. -1.69%+0.55%+91.07%+42.17%

Financials

2016 2017
Net sales 33.39L 28.73L 27.03L 24.69L 46.19L 32Cr 46.32L 3.19Cr 1.24Cr 16Cr 1.25Cr 1.23Cr 52Cr 61.8L 53.18L 50.03L 45.7L 85.5L 58Cr 85.73L 5.91Cr 2.29Cr 30Cr 2.32Cr 2.27Cr 96Cr
Net income 14.02L 12.07L 11.35L 10.37L 19.4L 13Cr 19.46L 1.34Cr 52.06L 6.79Cr 52.66L 51.51L 22Cr 24.1L 20.74L 19.51L 17.82L 33.34L 23Cr 33.43L 2.31Cr 89.46L 12Cr 90.49L 88.51L 38Cr
Net Debt - -
Logo Stemcell Holdings, Inc.
Stemcell Holdings, Inc. is engaged in the regenerative medicine-related business, which provides technical assistance to the culturing, storing and delivery of stem cells, administrative and consulting services to clinics. The Company provides two options for stem cell regenerative therapy: autologous adipose derived mesenchymal stem cells (ADMSC) and natural killer cells (NK). The Company provides coordination services to facilitate its stem cell culturing business. Its coordination services include the introduction of patients to clinics, arranging patients’ schedules, and translating between patients and clinics. The Company offers Internet marketing services by providing search engine optimization for clinics. It also offers property and equipment rental services. The Company operates through its wholly owned subsidiary, Stemcell Co., Ltd.
Employees
-
  1. Stock Market
  2. Stocks
  3. STMM Stock